AGLE — Aeglea Bio Therapeutics Share Price
Last Trade - 00:00- $319.63m
- $191.06m
- $13.70m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.63 | 5.21 | 3.89 | n/a | n/a | 11.67 | 15.6 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.
Directors
- Russell Cox NEC (57)
- Anthony Quinn PRE (59)
- Leslie Sloan COO (50)
- Steven Weber (44)
- Michael Hanley (48)
- Marcio Souza (41)
- Sara Brownstein (35)
- V. Bryan Lawlis (69)
- Alison Lawton (59)
- Ivana Magovcevic-Liebisch (53)
- Sandesh Mahatme (56)
- Armen Shanafelt IND (61)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- December 16th, 2013
- Public Since
- April 7th, 2016
- No. of Shareholders
- 21
- No. of Employees
- 88
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 49,023,640
- Address
- 805 Las Cimas Parkway, Suite 100, AUSTIN, 78746
- Web
- http://aegleabio.com
- Phone
- +1 5129422935
- Auditors
- PricewaterhouseCoopers LLP
Latest News for AGLE
Upcoming events for AGLE
Q3 2021 Aeglea Bio Therapeutics Inc Earnings Release
Similar to AGLE
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
FAQ
As of Today at 19:56 UTC, shares in Aeglea Bio Therapeutics are trading at $6.52. This share price information is delayed by 15 minutes.
Shares in Aeglea Bio Therapeutics last closed at $6.52 and the price had moved by -5.78% over the past 365 days. In terms of relative price strength the Aeglea Bio Therapeutics share price has underperformed the S&P500 Index by -28.52% over the past year.
The overall consensus recommendation for Aeglea Bio Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aeglea Bio Therapeutics does not currently pay a dividend.
Aeglea Bio Therapeutics does not currently pay a dividend.
Aeglea Bio Therapeutics does not currently pay a dividend.
To buy shares in Aeglea Bio Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.52, shares in Aeglea Bio Therapeutics had a market capitalisation of $319.63m.
Here are the trading details for Aeglea Bio Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AGLE
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Aeglea Bio Therapeutics does not currently have a style classification.
The analyst consensus target price for shares in Aeglea Bio Therapeutics is $15.00. That is 130.06% above the last closing price of $6.52.
Analysts covering Aeglea Bio Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aeglea Bio Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -20.82%.
As of the last closing price of $6.52, shares in Aeglea Bio Therapeutics were trading -13.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aeglea Bio Therapeutics.
Aeglea Bio Therapeutics' management team is headed by:
- Russell Cox - NEC
- Anthony Quinn - PRE
- Leslie Sloan - COO
- Steven Weber -
- Michael Hanley -
- Marcio Souza -
- Sara Brownstein -
- V. Bryan Lawlis -
- Alison Lawton -
- Ivana Magovcevic-Liebisch -
- Sandesh Mahatme -
- Armen Shanafelt - IND
We do not have data on Aeglea Bio Therapeutics' shareholders